Logo

BeyondSpring's Plinabulin Receives the US FDA's and NMPA's Breakthrough Therapy Designations for Chemotherapy-Induced Neutropenia Indication

Share this

BeyondSpring's Plinabulin Receives the US FDA's and NMPA's Breakthrough Therapy Designations for Chemotherapy-Induced Neutropenia Indication

Shots:

  • The designation is based on P-III PROTECTIVE-2 evaluating Plinabulin + Neulasta vs Neulasta alone for the treatment of CIN
  • In the protocol-specified interim analysis- combination regimen was better than Neulasta alone in achieving the 1EPs with p<0.01 and have a well-tolerated safety profile with fewer Grade 4 AEs
  • The company plans to report full results of the P-III PROTECTIVE-2 study in Q4’20 and file an NDA with the FDA by the end of 2020. The company has submitted an NDA to the NMPA on a rolling basis in Q1’20

 ­ Ref: GlobeNewswire | Image: Beyond Spring Pharma

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions